Clairvoyant Therapeutics
Clairvoyant Therapeutics is a Vancouver-based clinical-stage biotechnology company founded in 2021 developing psychedelic-based therapeutics under a speed-to-market clinical development strategy.
- Company typePrivate
- Founded2021
- HeadquartersVancouver, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Clairvoyant Therapeutics does
Clairvoyant Therapeutics is a Vancouver, Canada-based, privately-held biotechnology company founded in 2021 that is developing psychedelic-based therapeutics under a speed-to-market clinical strategy. The company positions itself to compress clinical development timelines in the psychedelic therapy space, with operational scale in the 11-50 employee range. No approved products, marketed therapies, commercial customers, or revenue-bearing operations are disclosed in the available material.
The company's financing history to date comprises two disclosed funding events: a late-2021 round of approximately $1.84 million led by Negev Capital, and a July 2022 round led by Origin Therapeutics (amount undisclosed). Total disclosed equity funding is approximately $1.84 million, indicating a very early, pre-Series A clinical posture. No pipeline candidates, named clinical programs, regulatory milestones (e.g., IND filings), partnership agreements, patents, leadership team, board composition, geographic operating footprint beyond Vancouver, or commercial GTM mechanics are present in the input data. A large block of source material in the input pertains to an unrelated entity (WIN4D, an Indonesian online gambling platform) and provides no usable signal about Clairvoyant Therapeutics' technology, products, customers, or revenue model.
Given the absence of pipeline detail, IP, partnerships, and commercial signals in the supplied material, any forward-looking assessment is constrained. The investment-relevant facts are: a Canadian biotech founded in 2021, focused on psychedelic therapeutics, with a small headcount and only seed-stage disclosed capital.
Clairvoyant Therapeutics firmographics
Firmographics- Name
- Clairvoyant Therapeutics
- Website
- https://clairvoyantrx.com
- Company type
- Private
- Founded year
- 2021
- Headcount range
- 11–50 employees
- Short description
- Clairvoyant Therapeutics is a Vancouver-based clinical-stage biotechnology company founded in 2021 developing psychedelic-based therapeutics under a speed-to-market clinical development strategy.
- Ownership category
- akta.pro rank
Clairvoyant Therapeutics industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)
Keywords
Where Clairvoyant Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Vancouver
- HQ country
- Canada
- HQ region
- North America
Markets served
Clairvoyant Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Online betting transactions: Platform generates revenue through player bets and transactions on various online betting games
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Transaction based/ take rate | Pay-as-you-go | Transaction-based gaming credits |
| Unit Pricing | Pay-as-you-go | E-commerce products |
Distribution channels2 records
Marketing channels3 records
Clairvoyant Therapeutics product offering
Product offeringCore offering
Clairvoyant Therapeutics is a biotechnology company developing psychedelic therapies, advancing candidates through clinical development using a speed-to-market clinical strategy.
Differentiator
Problem solved
Functional benefit
Companies that use Clairvoyant Therapeutics
Customer profileNamed customers3 records
Segments2 records
Clairvoyant Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Clairvoyant Therapeutics partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights2 records
Clairvoyant Therapeutics competitors and assessment
Company assessmentDirect peers
- Compass Pathways: Clinical-stage psychedelic therapy biotech developing psilocybin treatment for treatment-resistant depression. Most directly comparable to Clairvoyant given overlap on psilocybin-based therapy in behavioral health indications, though Compass is materially larger and later-stage.
- Mind Medicine (MindMed): Clinical-stage biotech developing psychedelic-inspired therapies (LSD, MDMA, psilocybin) for mental health. Closely comparable to Clairvoyant in psychedelic drug development for behavioral health, listed on Nasdaq with broader pipeline.
- ATAI Life Sciences: Platform biotech incubating and investing in multiple psychedelic therapy programs. Comparable as a psychedelic-focused developer serving behavioral health indications; broader portfolio and substantially more capital than Clairvoyant.
- Cybin Inc: Clinical-stage psychedelic therapeutics company developing psilocybin-based and deuterated psychedelic candidates for depression and addiction. Direct competitor in psychedelic drug development for behavioral health.
- GH Research: Clinical-stage biotech developing mebufotenin (5-MeO-DMT) therapies for treatment-resistant depression. Comparable as a small psychedelic drug developer targeting overlapping behavioral health indications.
- Small Pharma: Canadian clinical-stage biotech developing DMT-assisted therapy for major depressive disorder. Closely comparable to Clairvoyant on psychedelic drug development for behavioral health; similar early-stage profile and Canadian footprint.
- Beckley Psytech: Clinical-stage psychedelic medicine company developing psilocybin and other candidates for neurological and behavioral health indications. Direct peer in psychedelic drug development with comparable stage profile.
- Field Trip Health: Operator of ketamine-assisted psychotherapy clinics and developer of psychedelic therapies. Comparable on psychedelic therapy for behavioral health, with overlap on Canadian clinical operations and adjacent regulatory exposure.
Others
- Negev Capital: Cannabis- and psychedelic-focused investment fund that participated in Clairvoyant's seed round. Comparable as an ecosystem investor in psychedelic biotech rather than a product competitor.
- Origin Therapeutics: Public psychedelic-focused investment issuer that participated in Clairvoyant's 2022 financing. Adjacent comparable as a sector-specialist capital provider in the psychedelic biotech space.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Clairvoyant Therapeutics social profiles
Digital presenceClairvoyant Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Clairvoyant Therapeutics leadership team
Management profileNumber of profiles
Clairvoyant Therapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Clairvoyant Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Clairvoyant Therapeutics
What does Clairvoyant Therapeutics do?
Clairvoyant Therapeutics is a biotechnology company developing psychedelic therapies, advancing candidates through clinical development using a speed-to-market clinical strategy.
When was Clairvoyant Therapeutics founded?
Clairvoyant Therapeutics was founded in 2021. It employs 11 to 50 people.
Where is Clairvoyant Therapeutics based?
Clairvoyant Therapeutics is headquartered in Vancouver, Canada, in the North America region.
How does Clairvoyant Therapeutics make money?
One revenue line is on record: online betting transactions.
Who are Clairvoyant Therapeutics's main competitors?
Direct peers on record are Compass Pathways, Mind Medicine (MindMed), ATAI Life Sciences, Cybin Inc, GH Research, Small Pharma, Beckley Psytech and Field Trip Health. Others are Negev Capital and Origin Therapeutics.
Does Clairvoyant Therapeutics have an API?
No public API is recorded for Clairvoyant Therapeutics.
What industry is Clairvoyant Therapeutics in?
Clairvoyant Therapeutics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital). Its NAICS code is 541714 and its SIC code is 2834.